OBJECTIVE: To investigate the role of calcium/calmodulin-dependent protein kinase II (CaMKII) in myocardial ischemia-reperfusion (IR) injury in isolated perfused rat heart and explore the underlying mechanisms. METHODS: An ischemia-reperfusion (IR) model was prepared using isolated rat hearts perfused with Krebs-Henseleit solution were randomly divided into control group, 2.5 µmol/L KN-93 group, IR (induced by ischemia for 45 min followed by reperfusion for 120 min) group and KN-93+IR group. The myocardial performance was evaluated by assessing the left ventricular pressure. Lactate dehydrogenase (LDH) activity and cTnI content in the coronary flow and the infarct size were determined to evaluate the myocardial injury. The phosphorylation of CaMKII (p-CaMKII) and PLN (p-PLN) and oxidation of CaMKII (ox--CaMKII) were measured with Western blotting. The activity of mitochondrial superoxide dismutase (SOD) and the content of malondialdehyde (MDA) were determined using ELISA. RESULTS: Compared with the control group, KN-93 treatment at 2.5 µmol/L produced no significant effects on cardiac function or performance in rat hearts without IR injury. Myocardial IR injury significantly decreased myocardial performance and mitochondrial SOD activity in the perfused hearts (P<0.01) and caused significantly increased infarct size, LDH activity, cTnI content, expressions of p-CaMKII, ox-CaMKII and p-PLN, and also increased mitochondrial MDA content (P<0.01). KN-93 treatment at 2.5 µmol/L administered before ischemia and before reperfusion markedly attenuated such changes induced by ischemia and reperfusion (P<0.01). CONCLUSION: CaMKII participates in myocardial IR injury in isolated rat heart, and inhibiting CaMKII can alleviate myocardial injury by relieving mitochondrial oxidation stress.
OBJECTIVE: To investigate the role of calcium/calmodulin-dependent protein kinase II (CaMKII) in myocardial ischemia-reperfusion (IR) injury in isolated perfused rat heart and explore the underlying mechanisms. METHODS: An ischemia-reperfusion (IR) model was prepared using isolated rat hearts perfused with Krebs-Henseleit solution were randomly divided into control group, 2.5 µmol/L KN-93 group, IR (induced by ischemia for 45 min followed by reperfusion for 120 min) group and KN-93+IR group. The myocardial performance was evaluated by assessing the left ventricular pressure. Lactate dehydrogenase (LDH) activity and cTnI content in the coronary flow and the infarct size were determined to evaluate the myocardial injury. The phosphorylation of CaMKII (p-CaMKII) and PLN (p-PLN) and oxidation of CaMKII (ox--CaMKII) were measured with Western blotting. The activity of mitochondrial superoxide dismutase (SOD) and the content of malondialdehyde (MDA) were determined using ELISA. RESULTS: Compared with the control group, KN-93 treatment at 2.5 µmol/L produced no significant effects on cardiac function or performance in rat hearts without IR injury. Myocardial IR injury significantly decreased myocardial performance and mitochondrial SOD activity in the perfused hearts (P<0.01) and caused significantly increased infarct size, LDH activity, cTnI content, expressions of p-CaMKII, ox-CaMKII and p-PLN, and also increased mitochondrial MDA content (P<0.01). KN-93 treatment at 2.5 µmol/L administered before ischemia and before reperfusion markedly attenuated such changes induced by ischemia and reperfusion (P<0.01). CONCLUSION: CaMKII participates in myocardial IR injury in isolated rat heart, and inhibiting CaMKII can alleviate myocardial injury by relieving mitochondrial oxidation stress.
Authors: Yue Li; Syevda Sirenko; Daniel R Riordon; Dongmei Yang; Harold Spurgeon; Edward G Lakatta; Tatiana M Vinogradova Journal: Am J Physiol Heart Circ Physiol Date: 2016-07-08 Impact factor: 4.733
Authors: Lorna Daniels; James R Bell; Lea M D Delbridge; Fiona J McDonald; Regis R Lamberts; Jeffrey R Erickson Journal: Heart Fail Rev Date: 2015-09 Impact factor: 4.214
Authors: Haiyun Ling; Charles B B Gray; Alexander C Zambon; Michael Grimm; Yusu Gu; Nancy Dalton; Nicole H Purcell; Kirk Peterson; Joan Heller Brown Journal: Circ Res Date: 2013-02-06 Impact factor: 17.367
Authors: Gábor Koncsos; Zoltán V Varga; Tamás Baranyai; Kerstin Boengler; Susanne Rohrbach; Ling Li; Klaus-Dieter Schlüter; Rolf Schreckenberg; Tamás Radovits; Attila Oláh; Csaba Mátyás; Árpád Lux; Mahmoud Al-Khrasani; Tímea Komlódi; Nóra Bukosza; Domokos Máthé; László Deres; Monika Barteková; Tomáš Rajtík; Adriana Adameová; Krisztián Szigeti; Péter Hamar; Zsuzsanna Helyes; László Tretter; Pál Pacher; Béla Merkely; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy Journal: Am J Physiol Heart Circ Physiol Date: 2016-08-12 Impact factor: 4.733
Authors: Haiyun Ling; Tong Zhang; Laetitia Pereira; Christopher Kable Means; Hongqiang Cheng; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Ju Chen; Donald Bers; Joan Heller Brown; Joan Heller Brown Journal: J Clin Invest Date: 2009-04-20 Impact factor: 14.808
Authors: Adam S Helms; Francisco J Alvarado; Jaime Yob; Vi T Tang; Francis Pagani; Mark W Russell; Héctor H Valdivia; Sharlene M Day Journal: Circulation Date: 2016-09-29 Impact factor: 29.690
Authors: Mariano N Di Carlo; Matilde Said; Haiyun Ling; Carlos A Valverde; Verónica C De Giusti; Leandro Sommese; Julieta Palomeque; Ernesto A Aiello; Darlene G Skapura; Gustavo Rinaldi; Jonathan L Respress; Joan Heller Brown; Xander H T Wehrens; Margarita A Salas; Alicia Mattiazzi Journal: J Mol Cell Cardiol Date: 2014-06-17 Impact factor: 5.000